The Centers for Disease Control indicated in a warning on Tuesday that the vaccine could resume Johnson & Johnson as soon as Wednesday. The warning came after a chaotic day when the Food and Drug Administration recommended that there should be a “pause” for the vaccine, which led to each state stopping the use of the single-dose shot.
The CDC’s Advisory Committee on Immunization Practices will meet on Wednesday for an emergency session, with a vote on ‘updated recommendations for use’ before the group adjourns at 16:30 ET.
Dr. Anthony Fauci, chief medical adviser to President Biden, told CBS Evening News anchor Norah O’Donnell on Tuesday night that it appears the adverse effect occurred within six to 13 days, and ‘so if you had it for a month or two years ago, I think you do not really have to worry about anything. ‘
Fauci stressed that the chance of these negative side effects is ‘less than 1 in a million’, but he said he was aware of the symptoms such as severe headaches, difficult movements – as in a neurological situation – or discomfort on the chest and difficulty breathing.
As of Monday, more than 6.8 million doses of the Johnson & Johnson vaccine had been administered in the US, a small portion of the 190 million COVID vaccine shots given nationwide – most of them from Pfizer and Moderna.
The White House said on Tuesday that the interruption would have no significant impact on the nationwide vaccine plan. President Biden assured Americans that he had made sure the US had enough vaccine doses for all American adults from Pfizer and Moderna alone.
The handful of cases investigated by the FDA and CDC have occurred in women and were, according to their statement, a blood clot called cerebral venous sinus thrombosis, which was seen along low-level platelets. Symptoms were seen six to 13 days after vaccination in women between the ages of 18 and 48 years.
“The treatment of this particular type of blood clot is different from the treatment that can usually be given. Usually, an anticoagulant called heparin is used to treat blood clots. they said.
The agencies said the “adverse events” seem extremely rare, but that the break is important so that healthcare providers can be made aware of the reactions and properly recognize and manage the cases, given the unique treatment required.
Ed O’Keefe contributed to this report.